Aspirin can cut by more than half the risk that colon cancer will come back following initial treatment, a new clinical trial has found. Daily aspirin reduced by 55% the risk of cancer recurrence in patients whose colorectal cancer is driven by a genetic mutation, researchers reported Wednesday in the New England Journal of Medicine . "Aspirin is a drug that is readily available globally and extremely inexpensive compared to many modern cancer drugs, which is very positive," lead researcher